MorphoSys, which is licensing antibodies to pharmas and developing its own therapy for lymphoma, filed on Thursday with the SEC to raise up to $150 million in an initial public offering on the Nasdaq.
The company is currently listed on the Frankfurt Stock Exchange under the symbol MOR, with a market cap of €2.5 billion ($3.0 billion).
The Planegg, Germany-based company was founded in 1992 and booked €67 million in sales for the 12 months ended December 31, 2017. It plans to list on the Nasdaq under the symbol MOR. MorphoSys filed confidentially on February 2, 2018. Goldman Sachs, J.P. Morgan and Leerink Partners are the joint bookrunners on the deal. No pricing terms were disclosed.
